{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:03:05Z","timestamp":1756076585307},"reference-count":73,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.gtc.2011.06.011","type":"journal-article","created":{"date-parts":[[2011,9,7]],"date-time":"2011-09-07T07:16:57Z","timestamp":1315379817000},"page":"581-598","source":"Crossref","is-referenced-by-count":5,"title":["Hepatorenal Syndrome: Do the Vasoconstrictors Work?"],"prefix":"10.1016","volume":"40","author":[{"given":"Wesley","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2011.06.011_bib1","first-page":"1310","article-title":"Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis","volume":"56","author":"Salerno","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2011.06.011_bib2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2010.03.029","article-title":"Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites","volume":"8","author":"Montoliu","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(03)14903-3","article-title":"Hepatorenal syndrome","volume":"362","author":"Gin\u00e8s","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2011.06.011_bib4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/gut.2010.236133","article-title":"Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1016\/j.gtc.2011.06.011_bib5","first-page":"891A","article-title":"Are repeated episodes of acute renal dysfunction clinically significant in cirrhosis with ascites?","volume":"52","author":"Tsien","year":"2010","journal-title":"[Abstract] Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1097\/01.ASN.0000130340.93930.DD","article-title":"Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study","volume":"15","author":"Lassnigg","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.gtc.2011.06.011_bib7","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199808203390807","article-title":"Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis","volume":"339","author":"Martin","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2011.06.011_bib8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1053\/j.gastro.2008.03.007","article-title":"Portal hypertension and its complications","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2011.06.011_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0163-7258(01)00124-3","article-title":"The hyperdynamic circulation in cirrhosis: an overview","volume":"89","author":"Blendis","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.gtc.2011.06.011_bib10","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure and cirrhosis","volume":"361","author":"Gines","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gtc.2011.06.011_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/ki.2010.4","article-title":"Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome","volume":"77","author":"Oliver","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.gtc.2011.06.011_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2007.10.055","article-title":"Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis","volume":"134","author":"Stadlbauer","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2011.06.011_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s12072-008-9109-7","article-title":"Cirrhotic cardiomyopathy","volume":"3","author":"Wong","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.gtc.2011.06.011_bib14","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/jhep.2003.50447","article-title":"Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis","volume":"38","author":"Ruiz-del-Arbol","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/hep.20766","article-title":"Circulatory function and hepatorenal syndrome in cirrhosis","volume":"42","author":"Ruiz-del-Arbol","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/gut.2009.180570","article-title":"Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites","volume":"59","author":"Krag","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2011.06.011_bib17","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1111\/j.1440-1746.2009.05873.x","article-title":"Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis","volume":"24","author":"Narahara","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1080\/00365520310008728","article-title":"Effect of terlipressin on blood volume distribution in patients with cirrhosis","volume":"39","author":"Kiszka-Kanewitz","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1136\/gut.40.5.664","article-title":"Reduction in renal blood flow following acute increase in the portal pressure: evidence for the existence of a hepatorenal reflex in man?","volume":"40","author":"Jalan","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2011.06.011_bib20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/gast.2001.22529","article-title":"Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats","volume":"120","author":"Wiest","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2011.06.011_bib21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/hep.510310304","article-title":"Local arterial vasoconstriction induced by octreotide in patients with cirrhosis","volume":"31","author":"Chatila","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1572-0241.2005.41381.x","article-title":"Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison","volume":"100","author":"Baik","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/hep.510300430","article-title":"Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine","volume":"30","author":"G\u00fclberg","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy to terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib26","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(00)80158-0","article-title":"Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome","volume":"33","author":"Uriz","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib28","first-page":"15","article-title":"Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study","volume":"64","author":"Mulkay","year":"2001","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.gtc.2011.06.011_bib29","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","article-title":"Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study","volume":"36","author":"Ortega","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1440-1746.2003.02934.x","article-title":"Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial","volume":"18","author":"Solanki","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib31","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1053\/j.gastro.2008.02.014","article-title":"A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome","volume":"134","author":"Sanyal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2011.06.011_bib32","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1053\/j.gastro.2008.02.024","article-title":"Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study","volume":"134","author":"Mart\u00edn-Llah\u00ed","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2011.06.011_bib33","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1097\/MEG.0b013e32833a4822","article-title":"Effects of a single Terlipressin administration on cardiac function and perfusion in cirrhosis","volume":"22","author":"Krag","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib34","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.21901","article-title":"Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome","volume":"46","author":"Krag","year":"2007","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.gtc.2011.06.011_bib35","first-page":"378A","article-title":"Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (HRS) in patients with cirrhosis: results of a controlled clinical trial [abstract]","volume":"48","author":"Angeli","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/j.gastro.2009.03.064","article-title":"Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration","volume":"137","author":"Gerbes","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2011.06.011_bib37","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0168-8278(97)80428-X","article-title":"Time profile of the haemodynamic effects of terlipressin in portal hypertension","volume":"26","author":"Escorsell","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib38","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00042737-200212000-00013","article-title":"Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2","volume":"14","author":"Alessandria","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.510280407","article-title":"Acute effects of the oral administration of midodrine, an \u03b1-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites","volume":"28","author":"Angeli","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib40","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"The use of midodrine, octreotide and transjugular intrahepatic portosystemic stent shunt in the treatment of cirrhotic patients with ascites and renal dysfunction including hepatorenal syndrome","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1007\/s10620-006-9312-0","article-title":"Octreotide\/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome","volume":"52","author":"Esrailian","year":"2007","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2011.06.011_bib43","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MCG.0b013e318188947c","article-title":"Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome","volume":"43","author":"Skagen","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib44","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1053\/jhep.2002.34343","article-title":"Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: a pilot study","volume":"36","author":"Duvoux","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib45","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jhep.2007.04.010","article-title":"Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study","volume":"47","author":"Alessandria","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib46","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1572-0241.2008.01828.x","article-title":"An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response","volume":"103","author":"Sharma","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib47","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/j.1572-0241.2007.01390.x","article-title":"Octreotide enhances portal pressure reduction induced by propranolol in cirrhosis: a randomized, controlled trial","volume":"102","author":"Vorobioff","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib48","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0168-8278(97)80111-0","article-title":"Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis","volume":"26","author":"Moller","year":"1997","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib49","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib50","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/ndt\/gfh930","article-title":"Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study","volume":"20","author":"Kiser","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.gtc.2011.06.011_bib51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/ncpgasthep0680","article-title":"Drug insight: the role of albumin in the management of chronic liver disease","volume":"4","author":"Wong","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib52","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10620-007-9919-9","article-title":"Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome","volume":"53","author":"Neri","year":"2008","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2011.06.011_bib53","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0168-8278(99)80194-9","article-title":"Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial","volume":"30","author":"Gentilini","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib54","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3748\/wjg.v12.i9.1403","article-title":"Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial","volume":"12","author":"Romanelli","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib55","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1111\/j.1572-0241.2005.00271.x","article-title":"Treatment o f hepatorenal syndrome as defined by the International Ascites Club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study","volume":"100","author":"Peron","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib56","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.1440-1746.2009.06132.x","article-title":"Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials","volume":"25","author":"Sagi","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib57","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/hep.23286","article-title":"Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome","volume":"51","author":"Gluud","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.dld.2008.09.014","article-title":"Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study","volume":"41","author":"Alessandria","year":"2009","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gtc.2011.06.011_bib59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.23283","article-title":"Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome","volume":"51","author":"Nazar","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib60","article-title":"Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics","author":"Boyer","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib61","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/hep.20262","article-title":"Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome","volume":"40","author":"Wong","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib62","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1021763221337","article-title":"Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis","volume":"48","author":"Cassinello","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gtc.2011.06.011_bib63","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ndt\/gfi212","article-title":"The course of type 1 hepatorenal syndrome post liver transplantation","volume":"21","author":"Marik","year":"2006","journal-title":"Nephro Dial Transplant"},{"key":"10.1016\/j.gtc.2011.06.011_bib64","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1053\/jhep.2002.33160","article-title":"Pre-transplant renal function predicts survival in patients undergoing orthotopic liver transplantation","volume":"35","author":"Nair","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gtc.2011.06.011_bib65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pre-transplant renal function on survival after liver transplantation","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.gtc.2011.06.011_bib66","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2003.09.019","article-title":"Effects of treatment of hepatorenal syndrome before transplantation on post-transplantation outcome","volume":"40","author":"Restuccia","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.gtc.2011.06.011_bib67","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/00365520801932944","article-title":"Prediction of survival after liver transplantation by pre-transplant parameters","volume":"43","author":"Weismuller","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gtc.2011.06.011_bib68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/MOT.0b013e328338f638","article-title":"Combined liver and kidney transplantation","volume":"15","author":"Papafragkakis","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.gtc.2011.06.011_bib69","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/j.1523-1755.2005.00408.x","article-title":"Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy","volume":"68","author":"Wong","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.gtc.2011.06.011_bib70","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/j.1600-6143.2007.01856.x","article-title":"Simultaneous liver-kidney transplantation: evaluation to decision making","volume":"7","author":"Davis","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.gtc.2011.06.011_bib71","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1432-2277.2009.00887.x","article-title":"Combined liver-kidney and liver transplantation in patients with renal failure outcomes in the MELD era","volume":"22","author":"Schmitt","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.gtc.2011.06.011_bib72","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/TP.0b013e318168476d","article-title":"Declining outcomes in simultaneous liver-kidney transplantation in the MELD era: ineffective usage of renal allografts","volume":"85","author":"Locke","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.gtc.2011.06.011_bib73","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1478-3231.2006.01302.x","article-title":"Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study","volume":"26","author":"Schepke","year":"2006","journal-title":"Liver Int"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985531100063X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985531100063X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T01:56:11Z","timestamp":1560563771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985531100063X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":73,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S088985531100063X"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2011.06.011","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}